Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distress syndrome. The highest risk of severe traction...
Saved in:
Main Authors: | M. D. Suprun, T. V. Beketova, V. V. Babak, M. D. Evsikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ophthalmology Publishing Group
2022-07-01
|
Series: | Oftalʹmologiâ |
Subjects: | |
Online Access: | https://www.ophthalmojournal.com/opht/article/view/1876 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
by: T. V. Beketova, et al.
Published: (2021-07-01) -
Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01) -
Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01) -
Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody–Associated Vasculitis
by: Tania Salehi, et al.
Published: (2025-07-01) -
The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
by: T. V. Beketova, et al.
Published: (2021-03-01)